Blueprint Medicines (BPMC) Misses Q3 EPS by 37c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat